ulcerative colitis. The purpose of this study it to determine the impact of ustekinumab trough levels and clinical outcomes in patients with inflammatory bowel disease. Methods: This is an investigational review board (IRB) approved retrospective cohort study of adult IBD patients seen at the ULP Gastroenterology Office between January 1, 2016 and December 31, 2022. Patients 18 years of age and older who have a diagnosis of either Crohn's disease or ulcerative colitis and have been initially infused with ustekinumab will be included in the study. Patients on any maintenance dose of ustekinumab at a dosing frequency longer than 8 weeks or currently using another biologic will be excluded. Patients with both types of IBD will be divided into 3 treatment arms: ustekinumab trough levels ,2.0, trough levels 2.0 to 4.5, and trough levels . 4.5. The primary endpoint will be Crohn's Disease Activity Index (CDAI) in Crohn's disease and Simple Clinical Colitis Activity Index (SCCAI) in ulcerative colitis. Key secondary endpoints include bio-naïve versus bio-experienced status, endoscopic healing, concurrent use of Epigallocatechin Gallate, albumin and inflammatory lab values, and smoking status. This study will look at the correlation between ustekinumab trough levels and these clinical outcomes in both Crohn's disease and ulcerative colitis. Results: Results pending. Conclusion(s): Conclusion to be determined.

No abstract

ObjectivesPancreatic mass lesions are often solitary, although rarely synchronous pancreatic masses are encountered. No study has compared synchronous lesions with solitary lesions in the same population. The aim of the present study was to determine the prevalence, clinical, radiographic, and histologic findings of multiple pancreatic masses on consecutive patients undergoing endoscopic ultrasound (EUS) for pancreatic mass lesion.MethodsAll patients undergoing EUS for pancreatic mass lesions with histologic sampling over a 5-year span were identified. Charts were abstracted for demographics, medical history, radiographic findings, EUS findings, and histology and were reviewed.ResultsA total of 646 patients were identified, of which 27 patients (4.18%) had more than 1 pancreatic mass on EUS or cross-sectional imaging. The 2 groups were comparable with each other in terms of demographic factors and medical history. The 2 cohorts were comparable in location of the largest pancreas lesion and EUS characteristics. Patients with synchronous mass lesions were more likely to have metastatic lesions (P = 0.01). No other differences in histology were noted between the 2 groups.ConclusionsPatients with multiple pancreatic mass lesions were more likely to have metastatic lesions compared with patients with solitary lesions.

No abstract